For decades, Western pharmaceutical giants controlled the global market with an iron grip. Backed by stringent intellectual property laws, they set prices that made life-saving therapies accessible only to the wealthy elite. Yet today, India stands as the undisputed “Pharmacy of the Developing World,” manufacturing high-quality generic equivalents of the world’s most expensive medicines for pennies on the dollar. Western critics called it theft; in reality, it was one of the most brilliant legal and legislative strategies in modern economic history.

The narrative that India “stole” foreign medicine stems from a fundamental misunderstanding of national sovereignty and international trade governance. India did not engage in piracy, illicit smuggling, or black-market counterfeiting. Instead, it meticulously engineered its domestic patent laws, leveraged provisions within global trade agreements, and deployed judicial oversight to defeat corporate monopolies. In doing so, India created a legal sanctuary for low-cost generic drug manufacturing without ever violating international law.

1. The 1970 Revolution: Process Over Product

The foundation of India’s generic empire was laid shortly after independence. In the 1960s, drug prices in India were among the highest in the world, largely because Western multinational corporations held sweeping “product patents.” A product patent grants absolute exclusivity over the chemical molecule itself—regardless of how it is made. As a result, foreign firms maintained complete monopolies over essential medications.

In 1970, Prime Minister Indira Gandhi’s government enacted the landmark Indian Patents Act of 1970, following the recommendations of the Ayyangar Committee Report. The Act made a radical distinction: it abolished product patents for pharmaceuticals and agricultural products, replacing them strictly with process patents.

The Process Patent Loophole: Under the 1970 Act, an Indian firm could not be sued for making the same chemical compound as a Western company, provided they invented a slightly different, more efficient chemical path to produce it. This process—known as reverse engineering—allowed Indian pharma to legalise domestic generic production instantly.

Domestic companies like Cipla, Ranbaxy, and Dr. Reddy’s Laboratories mastered reverse engineering. They created alternative synthesis routes for life-saving drugs, bypassing Western monopolies legally. Within a decade, drug prices in India plummeted, and a domestic manufacturing infrastructure emerged that was capable of competing on a global scale.

2. Section 3(d): Defeating the “Evergreening” Industrial Complex

By the 1990s, Western nations fought back through the World Trade Organization (WTO). The 1994 Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement required all member states to reinstate product patents by 2005. India signed the agreement, leading Western drugmakers to assume that India’s generic boom was coming to an end.

However, Indian lawmakers engineered a masterstroke while amending the Patents Act in 2005: the inclusion of Section 3(d).

In global pharmaceutical strategy, “evergreening” is a common tactic used to extend monopolies. When a drug’s original 20-year patent approaches expiration, a company will make minor modifications—such as creating a new salt formulation, a crystalline form, or a slightly revised delivery mechanism—and apply for a new 20-year patent. This practice effectively blocks generic competition indefinitely.

Section 3(d) blocked this practice by declaring that new forms of existing substances are not patentable unless they demonstrate a significant increase in therapeutic efficacy. Minor chemical tweaks, new dosages, or pure reformulations were explicitly excluded from patent protection.

“Intellectual property rights must balance private profit with the fundamental human right to life and health. Section 3(d) ensured patents were reserved for true innovations, not corporate extensions.”

This provision faced its ultimate test in the landmark Supreme Court of India case Novartis v. Union of India (2013). Swiss pharmaceutical giant Novartis sought a patent for Glivec, a revolutionary leukemia drug. Novartis had patented the base molecule earlier and was now seeking a patent on its specific salt form (imatinib mesylate). The Indian Supreme Court rejected the claim, ruling that the salt form did not offer enhanced therapeutic efficacy under Section 3(d).

The impact was staggering: while Novartis charged approximately $2,600 per month for Glivec in Western markets, Indian generic producers immediately supplied the identical drug to cancer patients for under $175 per month.

3. Section 84: Weaponizing Compulsory Licensing

Even under full TRIPS compliance, international law preserves a nation’s sovereign right to protect public health. The 2001 WTO Doha Declaration explicitly affirmed that the TRIPS Agreement does not and should not prevent members from taking measures to protect public health, granting countries the right to issue Compulsory Licenses (CL).

Under Section 84 of the Indian Patents Act, the government can force a foreign patent holder to license its drug to a domestic generic manufacturer if three conditions are met:

1. The reasonable requirements of the public with respect to the patented invention have not been satisfied.
2. The patented invention is not available to the public at a reasonably affordable price.
3. The patented invention is not being worked (manufactured) within the territory of India.

In 2012, India executed its first landmark compulsory license against German drugmaker Bayer for its kidney and liver cancer medication, Nexavar. Bayer was selling Nexavar in India at roughly $5,500 per month—a price completely out of reach for over 99% of the local population. Indian generic firm Natco Pharma petitioned for a compulsory license, demonstrating that Bayer met all three failure criteria under Section 84.

• Bayer Nexavar (Patented): ~$5,500 / month
• Natco Generic (Compulsory License): ~$175 / month (with a mandatory 6% royalty paid to Bayer)

The Indian Patent Controller granted the license. Natco began manufacturing the drug at a 97% discount while paying Bayer a legally mandated royalty. Bayer appealed the decision all the way to the Indian Supreme Court and lost, solidifying the precedent that exorbitant pricing in developing markets constitutes a failure of patent duties.

4. The Global Impact: Saving Millions Beyond India

The legal architecture developed within India had profound consequences far beyond its borders. The most significant example occurred during the global HIV/AIDS pandemic in the late 1990s and early 2000s.

At the time, Western pharmaceutical companies charged over $10,000 to $15,000 per patient per year for the Triple Antiretroviral Therapy required to keep HIV patients alive. This price tag effectively signed a death sentence for tens of millions of people across sub-Saharan Africa and Asia.

In 2001, Cipla’s chairman, Dr. Yusuf Hamied, utilized India’s legal generic framework to reverse-engineer the triple combination therapy. He offered it to international aid agencies like Doctors Without Borders (MSF) for $350 per patient per year—less than $1 a day. Later, the price fell below $100 per year.

This single move broke the cartel pricing of Western pharmaceutical firms, forced global price reductions, and formed the backbone of programs like the US President’s Emergency Plan for AIDS Relief (PEPFAR). Today, over 80% of the antiretroviral drugs used to treat HIV globally are manufactured in India.

Legality, Morality, and the Future of Medicine

The claim that India “stole” the world’s most expensive medicines is a rhetorical shield used by multinational pharmaceutical companies defending high profit margins. What India actually accomplished was a masterclass in statutory law and international arbitration.

By utilizing process patents, enacting strict statutory barriers against evergreening, and executing compulsory licensing safeguards built directly into WTO frameworks, India proved that public health and legal compliance can coexist. India did not break international law—it mastered it, creating a blueprint for how sovereign nations can prioritize human survival over corporate monopoly.

About The Author